SOURCE: BIOLASE Technology, Inc.

January 31, 2007 07:30 ET

BIOLASE Announces FDA Clearance of Its ezlase™ Soft Tissue Diode Laser

IRVINE, CA -- (MARKET WIRE) -- January 31, 2007 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ezlase™, a new soft tissue diode laser system (patents pending).

"The new ezlase laser system is an important component of our overall dental laser market strategy and the perfect complement to our flagship product, the Waterlase™ MD," commented Jeffrey W. Jones, President and CEO. "We have devoted significant resources to make BIOLASE the leader in dental lasers and in dental laser brand name recognition. Now that we have a strategic alliance with dental powerhouse Henry Schein, the timing couldn't be better to launch this hand-sized, state-of-the-art, feature-rich soft-tissue dental laser system. Once again, BIOLASE is setting the standard."

The new ezlase diode laser includes numerous benefits aimed at providing cleaner cutting and faster hemostasis, with excellent absorption in hemoglobin and oxyhemoglobin. Features include easy-to-use procedure-based presets accessed via an iPod®-like navigation wheel or color touch screen, ultralight fiber and handpiece, innovative low-cost disposable tips, infinite pulse combinations which deliver laser energy by dose, and wireless Bluetooth® foot pedal.

Jones added, "To our knowledge, this is the first commercialized dental laser offering a variety of procedure-based, single-use tips. The ezlase is based on an optimized, new 940nm laser system with pulse characteristics specifically engineered by BIOLASE to make more soft-tissue procedures minimally invasive, with improved clinical outcomes and increased patient comfort. The ezlase can comfortably be held in the palm of the dentist's hand."

FDA-cleared indications for the ezlase include incision, excision, vaporization, ablation and coagulation of oral soft tissues, including marginal and inter-dental gingival tissues and epithelial lining of free gingiva and numerous other specific indications for dental soft tissue procedures. Additional FDA-cleared indications include laser periodontal procedures, including laser soft tissue curettage and laser removal of diseased, infected, inflamed and necrosed soft tissue within the periodontal pocket, and sulcular debridement.

BIOLASE plans to formally launch the ezlase laser system at the upcoming Chicago Dental Society mid-winter meeting in February 2007. More information and images of the ezlase can be found via the internet at www.biolase.com/ezlase.

iPod is a registered trademark of Apple Inc. and Bluetooth is a registered trademark of Bluetooth SIG, Inc.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile™ system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:

    Jeffrey W. Jones
    President & CEO
    Richard L. Harrison
    Executive Vice President and CFO
    BIOLASE Technology, Inc.
    +1-949-361-1200

    Jill Bertotti
    Allen & Caron
    +1-949-474-4300